Medicine composition used for treating myocardial ischemia and preparation method thereof

A technique for myocardial ischemia and a composition is applied in the field of a pharmaceutical composition for protecting myocardial ischemia and its preparation, which can solve the problems of blood lipids, adverse effects of blood sugar, limitations of therapeutic drugs, difficulties in prevention and treatment, etc., and achieves correction of hemodynamics Disturbance, no toxic side effects, significant effect

Inactive Publication Date: 2016-06-29
张长青
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] With the development of modern medicine, myocardial ischemia has achieved rapid development in prevention, diagnosis, and treatment. However, due to its many complications and complex mechanisms, coupled with the limitations of therapeutic drugs, it has brought certain difficulties to the prevention and treatment work.
In the prior art, the simple use of drugs such as nitrates, calcium channel blockers or beta re

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] A pharmaceutical composition for protecting myocardial ischemia, mainly composed of the following components in parts by weight: 1.2 parts of dicoumarin, 1.0 parts of β-ecdysterone, 0.8 parts of betulin, and 1.2 parts of myristic acid , 0.2 parts of citrus lactones, 0.1 parts of antithrombotic drugs, 0.1 parts of naltrexone, 0.3 parts of menthol, 1.2 parts of kaempferol-3-rhamnoglucoside, 0.5 parts of phycocyanin, and 0.2 parts of erythropoietin 0.1 part of alginic acid, 0.1 part of ginsenoside, 0.1 part of catechin, 0.3 part of eicosapentaenoic acid, and 3.0 part of arabinogalactose. Wherein, the antithrombotic drug is enoxaparin sodium, nadroparin calcium or dalteparin sodium. The ginsenoside is ginsenoside Rg2. The biphenyl cyclooctene lignans are Schizandrin B.

[0023] The preparation method of the pharmaceutical composition for protecting myocardial ischemia comprises the following steps:

[0024] (1) Raw materials: weigh dicoumarin, β-ecdysterone, betulin, myr...

Embodiment 2

[0028] A pharmaceutical composition for protecting myocardial ischemia, mainly composed of the following components in parts by weight: 2.35 parts of dicoumarin, 2.0 parts of β-ecdysterone, 2.5 parts of betulin, and 2.4 parts of myristic acid , citrus lactone 0.5 parts, antithrombotic drugs 0.3 parts, naltrexone 0.65 parts, menthol 0.65 parts, kaempferol-3-rhamnoglucoside 1.6 parts, phycocyanin 1.25 parts, erythropoietin 0.35 parts 0.55 parts of alginic acid, 0.35 parts of ginsenosides, 0.15 parts of catechins, 0.75 parts of eicosapentaenoic acid, and 6.5 parts of arabinogalactose. Wherein, the antithrombotic drug is enoxaparin sodium, nadroparin calcium or dalteparin sodium. The ginsenoside is ginsenoside Rg2. The biphenyl cyclooctene lignans are Schizandrin B.

[0029] The preparation method of the pharmaceutical composition for protecting myocardial ischemia comprises the following steps:

[0030] (1) Raw materials: weigh dicoumarin, β-ecdysterone, betulin, myristic acid...

Embodiment 3

[0034] A pharmaceutical composition for protecting myocardial ischemia, mainly composed of the following components in parts by weight: 3.5 parts of dicoumarin, 3.0 parts of β-ecdysterone, 4.2 parts of betulin, and 3.6 parts of myristic acid , citrus lactone 0.8 parts, antithrombotic drugs 0.5 parts, naltrexone 1.2 parts, menthol 1.0 parts, kaempferol-3-rhamnoglucoside 2.0 parts, phycocyanin 2.0 parts, erythropoietin 0.5 parts 1.0 parts of alginic acid, 0.6 parts of ginsenosides, 0.2 parts of catechins, 1.2 parts of eicosapentaenoic acid, and 10 parts of arabinogalactose. Wherein, the antithrombotic drug is enoxaparin sodium, nadroparin calcium or dalteparin sodium. The ginsenoside is ginsenoside Rg2. The biphenyl cyclooctene lignans are Schizandrin B.

[0035] The preparation method of the pharmaceutical composition for protecting myocardial ischemia comprises the following steps:

[0036] (1) Raw materials: weigh dicoumarin, β-ecdysterone, betulin, myristic acid, citrus l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine composition used for treating myocardial ischemia and a preparation method thereof. The medicine composition used for treating myocardial ischemia is prepared from, by weight, 1.2-3.5 parts of bishydroxycoumarin, 1.0-3.0 parts of beta-ecdysterone, 0.8-4.2 parts of betulin, 1.2-3.6 parts of myristic acid, 0.2-0.8 part of bergapten, 0.1-0.5 part of anti-thrombotic medicine, 0.1-0.2 part of naltrexone, 0.3-1.0 part of menthol, 1.2-2.0 parts of kaempferol-3-rhamnoglucoside, 0.5-2.0 parts of phycocyanobilin, 0.2-0.5 part of erythropoietin, 0.1-1.0 part of alginic acid, 0.1-0.6 part of panaxoside, 0.1-0.2 part of catechinic acid, 0.3-1.2 parts of timnodonic acid and 3.0-10 parts of Arab galactose. The medicine composition used for treating myocardial ischemia is safe, effective, easy to prepare and free of toxic or side effect, can lower myocardial oxygen consumption, relieve myocardial metabolic disorder and correct hemodynamics disorder, has the remarkable effect on treating myocardial ischemia, and has the practical application value clinically for treating or preventing myocardial ischemia.

Description

technical field [0001] The invention relates to the technical field of cardiovascular disease medication, in particular to a pharmaceutical composition for protecting myocardial ischemia and a preparation method thereof. Background technique [0002] Cardiovascular and cerebrovascular diseases are collectively referred to as cardiovascular and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases in the heart, brain, and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and high blood pressure. . It is a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. Even with the most advanced and perfect treatment methods, more than 50% of the survivors of cerebrovascular accidents still cannot take care of themselves completely. The number of people dying from cardiovascular and cerebrovascular diseases is as high as 15 million every year, ranking first...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61P9/10A61K31/045A61K31/202A61K31/23A61K31/352A61K31/353A61K31/36A61K31/37A61K31/485A61K31/519A61K31/56A61K31/575A61K31/704A61K31/7048A61K31/714A61K31/715A61K31/734A61K31/785
CPCA61K45/06A61K9/1652A61K9/2059A61K9/4866A61K31/045A61K31/202A61K31/23A61K31/352A61K31/353A61K31/36A61K31/37A61K31/485A61K31/519A61K31/56A61K31/575A61K31/704A61K31/7048A61K31/714A61K31/715A61K31/734A61K31/785A61K2300/00
Inventor 张长青
Owner 张长青
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap